[at noodls] – Study Provides Support for SEAMLESS, an Ongoing, Phase 3, Registration-Directed Trial in Elderly Patients With Newly Diagnosed AML Updated Survival Data From a Pilot Study and Lead-In Phase of SEAMLESS … moreView todays social media effects on CYCCView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – BERKELEY HEIGHTS, N.J., Oct. 15, 2012 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), will host a conference call today to discuss updated data … moreView todays social media effects on CYCCView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – BERKELEY HEIGHTS, N.J., Oct. 2, 2012 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that … moreView todays social media effects on CYCCView the latest stocks trending across Twitter. Click to view dashboard […]
